vs
Side-by-side financial comparison of Ensysce Biosciences, Inc. (ENSC) and Q32 Bio Inc. (QTTB). Click either name above to swap in a different company.
Q32 Bio Inc. is the larger business by last-quarter revenue ($1.9M vs $1.9M, roughly 1.0× Ensysce Biosciences, Inc.). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -147.0%, a 3138.2% gap on every dollar of revenue.
Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.
ENSC vs QTTB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $1.9M |
| Net Profit | $-2.8M | $57.7M |
| Gross Margin | — | — |
| Operating Margin | -147.8% | — |
| Net Margin | -147.0% | 2991.2% |
| Revenue YoY | 44.4% | — |
| Net Profit YoY | 22.3% | 506.9% |
| EPS (diluted) | $-0.51 | $4.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | $1.9M | ||
| Q3 25 | $493.1K | $-220.0K | ||
| Q2 25 | $1.4M | $-284.0K | ||
| Q1 25 | $1.3M | $-371.0K | ||
| Q4 24 | $1.3M | $0 | ||
| Q3 24 | $3.4M | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-2.8M | $57.7M | ||
| Q3 25 | $-3.7M | $-7.4M | ||
| Q2 25 | $-1.7M | $-9.5M | ||
| Q1 25 | $-1.9M | $-11.0M | ||
| Q4 24 | $-3.6M | $-14.2M | ||
| Q3 24 | $661.8K | $-17.6M | ||
| Q2 24 | — | $-17.0M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | -147.8% | — | ||
| Q3 25 | -758.7% | 3444.1% | ||
| Q2 25 | -127.6% | 3229.2% | ||
| Q1 25 | -149.1% | 3296.0% | ||
| Q4 24 | -274.3% | — | ||
| Q3 24 | 18.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -147.0% | 2991.2% | ||
| Q3 25 | -756.3% | 3358.6% | ||
| Q2 25 | -126.4% | 3341.2% | ||
| Q1 25 | -147.4% | 2973.3% | ||
| Q4 24 | -273.4% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.51 | $4.70 | ||
| Q3 25 | $-1.29 | $-0.60 | ||
| Q2 25 | $-0.79 | $-0.78 | ||
| Q1 25 | $-1.39 | $-0.90 | ||
| Q4 24 | $-0.89 | $2.63 | ||
| Q3 24 | $1.00 | $-1.46 | ||
| Q2 24 | — | $-1.42 | ||
| Q1 24 | — | $-6.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3M | $48.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.2M | $42.0M |
| Total Assets | $7.5M | $61.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $48.3M | ||
| Q3 25 | $1.7M | $49.0M | ||
| Q2 25 | $2.2M | $54.8M | ||
| Q1 25 | $3.1M | $65.5M | ||
| Q4 24 | $3.5M | $78.0M | ||
| Q3 24 | $4.2M | $89.1M | ||
| Q2 24 | — | $97.7M | ||
| Q1 24 | — | $115.5M |
| Q4 25 | $3.2M | $42.0M | ||
| Q3 25 | $1.2M | $-18.4M | ||
| Q2 25 | $3.4M | $-12.2M | ||
| Q1 25 | $3.0M | $-4.0M | ||
| Q4 24 | $3.7M | $5.7M | ||
| Q3 24 | $6.9M | $18.3M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | — | $48.8M |
| Q4 25 | $7.5M | $61.8M | ||
| Q3 25 | $3.2M | $57.8M | ||
| Q2 25 | $5.6M | $66.1M | ||
| Q1 25 | $4.6M | $79.1M | ||
| Q4 24 | $5.6M | $92.3M | ||
| Q3 24 | $9.4M | $104.5M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | — | $152.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-6.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.11× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.5M | $-6.2M | ||
| Q3 25 | $-1.9M | $-4.2M | ||
| Q2 25 | $-2.7M | $-10.7M | ||
| Q1 25 | $-1.7M | $-12.5M | ||
| Q4 24 | $-764.1K | $-11.4M | ||
| Q3 24 | $-1.0M | $-19.5M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $-19.6M | ||
| Q2 24 | — | $-22.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.11× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -14.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
